Katiti Medical

Beijing Katiti Medical Technology is a clinical-stage biotechnology company focused on the development of next-generation cell therapies, including chimeric antigen receptor T-cell (CAR-T) and Tumor-Infiltrating Lymphocyte (TIL) treatments. Founded by alumni of the University of Pennsylvania's pioneering CAR-T research team, the company addresses the challenges of treating solid tumors through its proprietary DAP-CAR technology and "Super TIL" (ScTIL) platforms, which enhance T-cell persistence and microenvironment adaptability. Katiti's pipeline features multi-target CAR-T candidates for hematological malignancies and innovative armored cell therapies for refractory solid tumors like biliary tract and gastric cancers. The company aims to provide high-efficacy, low-cost cell therapies through its proprietary manufacturing and genetic engineering platforms.